Habib, Ali A. http://orcid.org/0000-0003-3432-9747
Klink, Andrew J.
Muppidi, Srikanth http://orcid.org/0000-0002-2773-2506
Parthan, Anju http://orcid.org/0000-0002-2357-9479
Sader, S. Chloe
Balanean, Alexandrina http://orcid.org/0000-0001-5540-0755
Gajra, Ajeet http://orcid.org/0000-0002-5929-0466
Nowak, Richard J. http://orcid.org/0000-0001-8438-482X
Howard, James F. Jr. http://orcid.org/0000-0002-7136-8617
,
Funding for this research was provided by:
Alexion, AstraZeneca Rare Disease
Article History
Received: 27 February 2024
Revised: 28 June 2024
Accepted: 5 July 2024
First Online: 25 July 2024
Declarations
:
: Ali A. Habib has served as a medical advisor and speaker on behalf of Alexion, AstraZeneca Rare Disease, and argenx; he has received research support from Alexion, AstraZeneca Rare Disease, and Cabaletta Bio; and has received research support and honoraria from argenx, UCB, Pfizer, Genentech, Viela Bio/Horizon, Sanofi, Immunovant Inc., and Regeneron. Andrew J. Klink is a salaried employee of and owns stock in Cardinal Health, which received funding from Alexion, AstraZeneca Rare Disease for work performed on this study. Srikanth Muppidi has served on advisory board meetings for Alexion, AstraZeneca Rare Disease, argenx, Horizon Therapeutics, and Ra Pharmaceuticals (now UCB). Anju Parthan was an employee of Alexion, AstraZeneca Rare Disease and owned stock in AstraZeneca at the time the study was conducted and analyzed. S. Chloe Sader is an employee of Alexion, AstraZeneca Rare Disease and owns stock in AstraZeneca. Alexandrina Balanean is a salaried employee of Cardinal Health, which received funding from Alexion, AstraZeneca Rare Disease for work performed on this study. Ajeet Gajra was a salaried employee of and owned stock in Cardinal Health (which received funding from Alexion, AstraZeneca Rare Disease for work performed on this study) at the time the study was conducted. Richard J. Nowak has received research support from Alexion, AstraZeneca Rare Disease, argenx, Genentech, Grifols, Immunovant, Inc., Momenta Pharmaceuticals, the Myasthenia Gravis Foundation of America, the National Institutes of Health (National Institute of Neurological Disorders and Stroke and National Institute of Allergy and Infectious Diseases), Ra Pharmaceuticals (now UCB), and Viela Bio Inc. (now Horizon Therapeutics); and consultancy fees from Alexion, AstraZeneca Rare Disease, argenx, Cour Pharmaceuticals, Grifols, Immunovant, Inc., Momenta Pharmaceuticals, Ra Pharmaceuticals (now UCB), Roivant Sciences, and Viela Bio (now Horizon Therapeutics). James F. Howard Jr. has received research support (paid to institution) from Ad Scientiam, Alexion, AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), NMD Pharma, PCORI, and UCB Pharma; honoraria from Alexion AstraZeneca Rare Disease, argenx, Biohaven Ltd, Biologix Pharma, CheckRare CME, F. Hoffman-LaRoche, Horizon Therapeutics (now Amgen), Medscape CME, Merck EMD Serono, NMD Pharma, Novartis Pharma, PeerView CME, Physicians’ Education Resource (PER) CME, PlatformQ CME, Regeneron Pharmaceuticals, Sanofi US, UCB Pharma, and Zai Labs; and non-financial support from Alexion, AstraZeneca Rare Disease, argenx, Toleranzia AB, UCB Pharma, and Zai Labs.
: The study was reviewed by the Western Institutional Review Board and determined exempt from requiring ethical approval on the basis that only secondary data were collected; that data included only the necessary protected health information to conduct the study (e.g., treatment dates, date of death); and that all data were reported in aggregate.